Q-linea AB (publ) (STO:QLINEA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 317.39M +49.3% |
| Revenue (ttm) | 11.81M +370.2% |
| Net Income | -170.83M |
| EPS | -15.76 |
| Shares Out | 18.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,997 |
| Average Volume | 20,584 |
| Open | 16.75 |
| Previous Close | 16.75 |
| Day's Range | 16.20 - 16.75 |
| 52-Week Range | 16.20 - 79.00 |
| Beta | 0.54 |
| RSI | 22.53 |
| Earnings Date | Apr 24, 2026 |
About Q-linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incu... [Read more]
Financial Performance
In 2025, Q-linea AB's revenue was 19.46 million, an increase of 370.16% compared to the previous year's 4.14 million. Losses were -182.49 million, -15.86% less than in 2024.
Financial StatementsNews
Q-linea AB (FRA:3F80) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Operational ...
Q-linea AB (FRA:3F80) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Operational Streamlining
Q-linea AB Earnings Call Transcript: Q1 2026
Record Q1 for instrument placements and consumables demand, driven by FDA V2 menu clearance in the U.S. and steady European growth. OpEx reduced 47% year-over-year, with a strong pipeline and new product launches expected to accelerate growth.
Q-linea AB (FRA:3F80) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Q-linea AB (FRA:3F80) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Restructuring
Q-linea AB Earnings Call Transcript: Q4 2025
Revenue grew over 400% year-over-year in 2025, driven by instrument placements and consumables. U.S. growth is expected to accelerate after FDA clearance in 2026, with breakeven targeted for 2027. OpEx reductions and strong liquidity position support continued expansion.
Q-linea AB (OSTO:QLINEA) Q3 2025 Earnings Call Highlights: Strong Demand and Strategic ...
Q-linea AB (OSTO:QLINEA) Q3 2025 Earnings Call Highlights: Strong Demand and Strategic Partnerships Amid Challenges
Q-linea AB Earnings Call Transcript: Q3 2025
Recurring income grew 370% year-over-year, driven by increased instrument activations and consumables demand, with a robust pipeline in over 15 countries. Cost reductions and a major rights issue secure liquidity, while FDA clearance for the V2 menu remains a key near-term catalyst.
Q-linea AB Earnings Call Transcript: Q2 2025
Q2 saw five new instrument placements, strong pipeline growth, and robust cost control. Financials improved year-over-year, with a completed capital raise and clear path to break-even by 2027. Italy leads adoption, while the U.S. and other regions are progressing through early stages.
Q-linea AB Earnings Call Transcript: Q1 2025
Record Q1 sales and five new contracts drove strong commercial momentum, with expanding U.S. and international presence. Cost control remains solid, and break-even is targeted for 2027, supported by new equity and ongoing efforts to secure non-dilutive funding.
Q-linea AB Earnings Call Transcript: Q4 2024
2024 saw Q-linea solidify its leadership in rapid AST, achieving FDA clearance, expanding commercial activities, and reducing costs. Financial stability hinges on a successful warrant subscription in May, while 2025 is set for accelerated growth in the U.S. and Europe.
Q-linea AB Earnings Call Transcript: Q3 2024
Targeting rapid AST market growth, the company expanded its U.S. and European pipeline, completed cost restructuring, and launched a SEK 225 million rights issue to fund pivotal commercial expansion. Q3 saw improved operating results and key reimbursement wins.
Q-linea AB Earnings Call Transcript: Q2 2024
FDA approval enabled US commercial launch and global expansion, while a cost-saving program exceeded expectations. Q2 saw low revenue due to the reagent rental model, but financing is secured and US market focus is expected to drive future growth.